Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4 Why Aridis Pharmaceuticals (ARDS) Shares Are Soaring Today – Aridis Pharmaceuticals (NASDAQ:ARDS) – Stocks to Watch
Aridis Pharmaceuticals IncARDS announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation.
AR-501 is being developed as a once-per-week inhaled dosing regimen self-administered using a commercially available nebulizer device.
The study’s primary and secondary safety and pharmacokinetics (PK) endpoints were met.
Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated. No drug-related serious adverse events (SAEs) were observed.
The majority of treatment-emergent adverse events (TEAEs) were respiratory in nature and primarily mild to moderate in severity.
CF patients achieved high uptake of AR-501 in the respiratory tract, as measured by sputum concentrations, at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa
Inhaled delivery achieved more than 10-fold higher respiratory uptake of gallium (AR-501) than past clinical studies of intravenous (IV) gallium, resulting in lung function improvement and P. aeruginosa reduction.
Price Action: ARDS shares are up 47.70% at $0.68 during the premarket session on the last check Monday.
